Continuous glucose monitoring (CGM)-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study
Authors' conclusion
Among insulin-treated older adults living with type 2 diabetes, glycemic variability was independently associated with all-cause mortality, highlighting its potential relevance for clinical management in geriatric diabetes care.
Study context
- Population
- Insulin-treated older adults with T2D aged 75 and older, on insulin for at least 6 months; mean age 81.5 years58 died
- Participants
- 141 adults
- Comparison
- CGM-derived metrics and all-cause mortality
- Primary endpoint
- All-cause mortality
- Follow-up
- Median 44 months
Methodological detailsmulticenter, ancillary study, blinded CGM (FreeStyle Libre Pro®) for 28 consecutive days, multivariable Cox regression
- Multicenter
- Ancillary study
- Blinded CGM (FreeStyle Libre Pro®) for 28 consecutive days
- Multivariable Cox regression
Primary result
As reported in the abstract
All-cause mortality per IQR% increase of CGM parameter (adjusted)
Hazard ratio (95% CI)
Level 1 TBR (per IQR% increase)
1.51(1.11–2.06)
Level 2 TBR (per IQR% increase)
1.25(1.02–1.53)
CV (per IQR% increase)
1.76(1.21–2.56)
Per IQR% increase, as printed
Further findings
Recommended CGM targets and mortality
| HR (CI) | ||
|---|---|---|
| CV ≤ 36% | 0.57 (0.32–0.99) | |
| 0.20.5125Hazard ratio (log scale) |
- TIR > 50% and time below range (TBR) ≤ 1% were not significantly associated with mortality
Original publication
CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study. Diabetes Metab. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →